Trofinetid (1) – Daybu®
Rett syndrome, ≥ 5 years
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | 01.04.2027 – active procedure |
| INN | Trofinetid |
| Brand name | Daybu® |
| Pharm. company | Acadia Pharmaceuticals (Germany) GmbH |
| G-BA Procedure ID | D-1381 |
| Therapeutic area | Mental illnesses Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
| Trofinetid (1) | Daybu® | Acadia Pharmaceuticals (Germany) GmbH | Rett syndrome, ≥ 5 years | n.d. | active procedure Orphan |
<< List of all resolutions